-
公开(公告)号：US5667967A
公开(公告)日：1997-09-16
申请号：US66325
申请日：1993-05-21
CPC分类号： C12Q1/6883 , G01N2800/285
摘要： Methods are provided for determining relations between autoimmune degenerative diseases and specific variable regions of T-cell receptors as associated with the host HLA or T-cells associated with umbatting neoprofilerative diseases. By identifying the particular T-cell receptors which cause or are the disease in mammals, various prophylactic and therapeutic techniques may be employed for inhibiting the attack of the T-cell receptors on the native protein or tissue enhance the defense. In addition, individuals may be diagnosed as to their propensity for a particular autoimmune disease or the occurrence of such a disease.
摘要翻译： 提供了用于确定自身免疫性退行性疾病与T细胞受体的特异性可变区之间的关系的方法，所述T细胞受体与与神经调节性新生儿疾病相关的宿主HLA或T细胞相关。 通过鉴定在哺乳动物中引起或者是疾病的特定T细胞受体，可以采用各种预防和治疗技术来抑制天然蛋白质或组织上的T细胞受体的攻击增强了防御性。 此外，个体可能被诊断为其对特定自身免疫疾病的倾向或这种疾病的发生。
-
公开(公告)号：US20150265691A1
公开(公告)日：2015-09-24
申请号：US11901234
申请日：2007-09-14
申请人： Denong Wang , Pavol Kovac , Lawrence Steinman , Gregory Carroll , Nicholas Turro , Jeffrey Koberstein , Rina Saksena , Roberto Adamo
发明人： Denong Wang , Pavol Kovac , Lawrence Steinman , Gregory Carroll , Nicholas Turro , Jeffrey Koberstein , Rina Saksena , Roberto Adamo
CPC分类号： A61K39/07 , A61K47/61 , A61K47/6415 , A61K47/646 , A61K2039/55566 , A61K2039/6068 , A61K2039/6081 , C07K16/1278 , C12Q1/04 , G01N33/56911 , G01N2333/32 , G01N2469/10
摘要： This invention provides a vaccine comprising (i) an anthrose-containing saccharide in an amount effective to enhance immunity against Bacillus anthracis in a subject and (ii) a pharmaceutically acceptable carrier. This invention provides a vaccine comprising (i) a conjugate of an anthrose-containing saccharide in an amount effective to enhance immunity against Bacillus anthracis in a subject, wherein the anthrose-containing saccharide is conjugated to a biomolecule via a linker, and (ii) a pharmaceutically acceptable carrier. This invention provides a method for vaccinating a subject against Bacillus anthracis infection comprising administering to the subject a vaccine comprising (i) an anthrose-containing saccharide in an amount effective to enhance immunity against Bacillus anthracis in the subject and (ii) a pharmaceutically acceptable carrier, in an amount effective to stimulate production of antibodies to Bacillus anthracis spores in the subject, thereby vaccinating the subject against Bacillus anthracis.
摘要翻译： 本发明提供了一种疫苗，其包含（i）含有量的含有糖的糖类，其量有效地增强受试者中对炭疽杆菌的免疫力，和（ii）药学上可接受的载体。 本发明提供了一种疫苗，其包含（i）含有含量的含糖的糖类的缀合物，其有效量以增强受试者中对炭疽芽孢杆菌的免疫力，其中所述含有所述含烟糖的糖通过接头与生物分子缀合，和（ii） 药学上可接受的载体。 本发明提供了一种针对炭疽芽孢杆菌感染接种受试者的方法，其包括向所述受试者施用疫苗，所述疫苗包含（i）含有有效量以提高受试者中对于炭疽杆菌的免疫力的含量的含有糖的糖类，以及（ii）药学上可接受的载体 ，其量有效地刺激在受试者中产生炭疽芽孢杆菌孢子的抗体，从而使受试者接种针对炭疽芽孢杆菌的疫苗。
-
公开(公告)号：US08771689B2
公开(公告)日：2014-07-08
申请号：US13135079
申请日：2011-06-23
IPC分类号： A61K39/395 , A61K38/00
CPC分类号： A61K38/1709 , A61K31/711 , A61K39/395 , A61K45/06 , A61K47/48415 , A61K47/6811 , A61K2039/505 , C07K16/18 , C07K2317/52 , C07K2317/75
摘要： The invention provides methods for treating inflammatory diseases by administering to the subject an effective amount of an agent that provides alpha B-crystallin activity, where the dose is effective to suppress or prevent initiation, progression, or relapses of disease, including the progression of established disease. In some embodiments, the methods of the invention comprise administering to a subject having a pre-existing inflammatory disease condition, an effective amount of alpha B-crystallin protein, to suppress or prevent relapses of the disease.
摘要翻译： 本发明提供了通过向受试者施用有效量的提供αB-晶状蛋白活性的药剂来治疗炎性疾病的方法，其中剂量有效地抑制或预防疾病的起始，进展或复发，包括已建立的 疾病。 在一些实施方案中，本发明的方法包括向具有预先存在的炎症疾病状况的受试者施用有效量的α-B-晶状蛋白，以抑制或预防疾病的复发。
-
4.发明申请公开(公告)号：US20130046015A1
公开(公告)日：2013-02-21
申请号：US13577579
申请日：2011-02-11
IPC分类号： A61K31/225 , A61P25/00 , A61P29/00
CPC分类号： A61K31/225 , A61K31/18 , G01N33/6863 , G01N33/6896 , G01N2333/54 , G01N2800/285 , Y02A90/26
摘要： Compositions and methods are provided for the treatment of IL-17-type inflammatory demyelinating diseases with inhibitors of granulocyte function, e.g. elastase inhibitors. Diseases of interest include multiple sclerosis, neuromyelitis optica, animal models of such diseases, etc. In some embodiments pharmaceutical formulations comprising an elastase inhibitor in an effective dose for treatment of IL-17-type inflammatory demyelinating disease and a pharmaceutically acceptable excipient are provided. Patients may be classified into subtypes prior to treatment, which subtypes are informative of the patient's need for therapy and responsiveness to a therapy of interest.
摘要翻译： 提供组合物和方法用于治疗IL-17型炎性脱髓鞘疾病与粒细胞功能抑制剂，例如， 弹性蛋白酶抑制剂。 感兴趣的疾病包括多发性硬化症，视神经脊髓炎，这种疾病的动物模型等。在一些实施方案中，提供了包含用于治疗IL-17型炎性脱髓鞘疾病的有效剂量的弹性蛋白酶抑制剂和药学上可接受的赋形剂的药物制剂。 患者可以在治疗之前分为亚型，哪些亚型对患者的治疗需求和对感兴趣的治疗的反应性是有益的。
-
公开(公告)号：US08071744B2
公开(公告)日：2011-12-06
申请号：US13096643
申请日：2011-04-28
申请人： Thijs Kaper , Michael Platten , Lawrence Steinman , Wolf Frommer
发明人： Thijs Kaper , Michael Platten , Lawrence Steinman , Wolf Frommer
IPC分类号： C12N15/62
CPC分类号： G01N33/6872 , G01N33/5008 , G01N2333/70596 , G01N2800/24
摘要： The present invention provides methods for detecting changes in tryptophan concentrations in a cell and methods for identifying agents that modulate cellular tryptophan concentrations. In particular, the present invention provides methods for detecting cellular exchange between tryptophan and kynurenine, and methods for identifying agents that modulate this exchange. The present invention also provides methods for treating a disease associated with immunosuppression in a subject in need thereof. In particular, the present invention is directed toward a method of treating a disease associated with immunosuppression comprising contacting the disease with an agent that modulates cellular Trp/kynurenine exchange. Furthermore, the present invention provides methods for identifying an agent that modulates an immunosuppression.
摘要翻译： 本发明提供了用于检测细胞中色氨酸浓度变化的方法以及鉴定调节细胞色氨酸浓度的试剂的方法。 特别地，本发明提供了检测色氨酸和犬尿氨酸之间的细胞交换的方法，以及用于鉴定调节该交换的试剂的方法。 本发明还提供了在有需要的受试者中治疗与免疫抑制相关的疾病的方法。 特别地，本发明涉及一种治疗与免疫抑制相关的疾病的方法，其包括将疾病与调节细胞Trp /犬尿苷交换的药物接触。 此外，本发明提供了鉴定调节免疫抑制的药剂的方法。
-
公开(公告)号：US20110223657A1
公开(公告)日：2011-09-15
申请号：US13096643
申请日：2011-04-28
申请人： Thijs Kaper , Michael Platten , Lawrence Steinman , Wolf Frommer
发明人： Thijs Kaper , Michael Platten , Lawrence Steinman , Wolf Frommer
CPC分类号： G01N33/6872 , G01N33/5008 , G01N2333/70596 , G01N2800/24
摘要： The present invention provides methods for detecting changes in tryptophan concentrations in a cell and methods for identifying agents that modulate cellular tryptophan concentrations. In particular, the present invention provides methods for detecting cellular exchange between tryptophan and kynurenine, and methods for identifying agents that modulate this exchange. The present invention also provides methods for treating a disease associated with immunosuppression in a subject in need thereof. In particular, the present invention is directed toward a method of treating a disease associated with immunosuppression comprising contacting the disease with an agent that modulates cellular Trp/kynurenine exchange. Furthermore, the present invention provides methods for identifying an agent that modulates an immunosuppression.
摘要翻译： 本发明提供了用于检测细胞中色氨酸浓度变化的方法以及鉴定调节细胞色氨酸浓度的试剂的方法。 特别地，本发明提供了检测色氨酸和犬尿氨酸之间的细胞交换的方法，以及用于鉴定调节该交换的试剂的方法。 本发明还提供了在有需要的受试者中治疗与免疫抑制相关的疾病的方法。 特别地，本发明涉及一种治疗与免疫抑制相关的疾病的方法，其包括将疾病与调节细胞Trp /犬尿苷交换的药物接触。 此外，本发明提供了鉴定调节免疫抑制的药剂的方法。
-
公开(公告)号：US20110160142A1
公开(公告)日：2011-06-30
申请号：US12931001
申请日：2011-01-21
CPC分类号： A61K31/711 , A61K38/1709
摘要： The invention provides methods for treating inflammatory diseases by administering to the subject an effective amount of an agent that provides alpha B-crystallin activity, where the dose is effective to suppress or prevent initiation, progression, or relapses of disease, including the progression of established disease. In some embodiments, the methods of the invention comprise administering to a subject having a pre-existing inflammatory disease condition, an effective amount of alpha B-crystallin protein, to suppress or prevent relapses of the disease.
摘要翻译： 本发明提供了通过向受试者施用有效量的提供αB-晶状蛋白活性的药剂来治疗炎性疾病的方法，其中剂量有效地抑制或预防疾病的起始，进展或复发，包括已建立的 疾病。 在一些实施方案中，本发明的方法包括向具有预先存在的炎症疾病状况的受试者施用有效量的α-B-晶状蛋白，以抑制或预防疾病的复发。
-
公开(公告)号：US20100129376A1
公开(公告)日：2010-05-27
申请号：US12546204
申请日：2009-08-24
IPC分类号： A61K39/395 , C07K16/18 , A61P19/02 , A61P25/28 , A61P37/00 , G01N33/566 , G01N33/53
CPC分类号： C12N15/8509 , A01K67/0276 , A01K2217/05 , A01K2217/075 , A01K2227/105 , A01K2267/03
摘要： Monoclonal antibodies immunospecific for osteopontin are disclosed. Also provided are therapeutic methods of use thereof for modulating osteopontin levels for the treatment of autoimmune disorders.
摘要翻译： 公开了针对骨桥蛋白免疫特异性的单克隆抗体。 还提供了用于调节骨桥蛋白水平用于治疗自身免疫性疾病的治疗方法。
-
9.发明申请公开(公告)号：US20080166339A1
公开(公告)日：2008-07-10
申请号：US11999099
申请日：2007-12-03
申请人： Sawsan Youssef , Eun Mi Hur , Lawrence Steinman
发明人： Sawsan Youssef , Eun Mi Hur , Lawrence Steinman
IPC分类号： A61K39/395 , A61K31/70 , A61P37/00
CPC分类号： C07K16/24 , A61K31/711 , A61K2039/505
摘要： Methods are provided for the inhibition or prevention of relapses in pre-existing autoimmune disease by decreasing activity or expression of osteopontin in immune cells found in tissues affected by the autoimmune disease. Osteopontin is shown herein to mediate autoimmune relapses and induce a shift to the secondary or progressive stage in autoimmune disease. Osteopontin promotes the survival of activated T cells through regulation of transcription factors, FoxO3a and NF-κB and via the expression of pro-apoptotic proteins.
摘要翻译： 提供了通过降低受自身免疫疾病影响的组织中发现的免疫细胞中骨桥蛋白的活性或表达来抑制或预防预先存在的自身免疫疾病中的复发的方法。 本文显示骨桥蛋白介导自身免疫性复发并诱导自身免疫性疾病转为继发或进行阶段。 骨桥蛋白通过调节转录因子FoxO3a和NF-κB并通过促凋亡蛋白的表达促进活化的T细胞的存活。
-
公开(公告)号：US07070780B2
公开(公告)日：2006-07-04
申请号：US10152654
申请日：2002-05-20
申请人： Lawrence Steinman , Pedro Jose Ruiz
发明人： Lawrence Steinman , Pedro Jose Ruiz
CPC分类号： C07K14/4713 , A61K38/02 , A61K39/00
摘要： Compositions and methods are provided for the treatment of demyelinating autoimmune disease. Therapeutic doses are administered of an ordered peptide comprising a repeated motif {SEQ ID NO: 1} [1E2Y3Y4K]n, where n is from 2 to 6. Some specific peptides of interest include those having the sequence {SEQ ID NO:4} EYYKEYYKEYYK. The peptide may consist only of the ordered repeats, or may be extended at either termini by the addition of other amino acid residues. For therapy, the peptides may be administered topically or parenterally, e.g. by injection at a particular site, including subcutaneously, intraperitoneally, intravascularly, or the like or transdermally, as by electrotransport. In a preferred embodiment, subcutaneous injection is used to deliver the peptide. The subject methods are used for prophylactic or therapeutic purposes. The compositions of the invention may also contain other therapeutically active agents, e.g. immunosuppressants, β-interferon, steroids, etc.
摘要翻译： 提供组合物和方法用于治疗脱髓鞘性自身免疫性疾病。 给予治疗剂量的有序肽，其包含重复基序（SEQ ID NO：1）[SEQ ID NO：1] / SEQ ID NO：1 / 其中n为2至6.感兴趣的某些特定肽包括具有序列（SEQ ID NO：4）EYYKEYYYYYYK的那些。 肽可以仅由有序重复组成，或者可以通过加入其它氨基酸残基在任一末端延伸。 对于治疗，肽可以局部或肠胃外给药，例如， 通过在特定部位注射，包括皮下，腹膜内，血管内等或通过电转运进行皮下注射。 在优选的实施方案中，皮下注射用于递送肽。 本发明方法用于预防或治疗目的。 本发明的组合物还可以含有其它治疗活性剂，例如， 免疫抑制剂，β-干扰素，类固醇等
-
-
-
-
-
-
-
-
-
搜索结果
58 条记录 (耗时 0.041 秒)